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Aromatase is an influential target to overcome estrogen receptor positive breast cancer, as the enzyme is responsible for 
conversion of androstenedione to estrone, a promising drug target for therapeutic management of breast cancer. Chalcones 
are prominent biosynthetic compounds and parent candidate for the synthesis of heterocycles with diversified biological 
activities. The prime objective of the present study is to evaluate the binding interaction of 2-hydroxyphenyl- prop-2-en-1-
one (1A-1X), 2-hydroxy-4-methoxyphenyl- prop-2-en-1-one (3A-3X), 2,4-dihydroxyphenyl- prop-2-en-1-one (9A-9X) and 
1-hydroxynaphthalen-2-yl-prop-2-en-1-one (5A-5X) derivatives with aromatase enzyme by molecular docking study and 
also check their ADME properties by maestro suit. The designed chalcones derivatives have been docked against our target 
protein with PDB id 3S7S retrieved from the protein data bank, whereas exemestane has been taken as the positive control. 
As docking data revealed that docking score of 1K, 1U, 1B 3K 3N, 5K, 5U, 9S, 9K, 9N and 9F compounds found less than 
exemestane and all of these compounds with appropriate ADME properties have proven their excellent absorption as well as 
solubility characteristics. The present findings provided valuable information about binding interactions of chalcones 
derivatives to the active site of aromatase. These compounds may serve as potential lead compound for developing new 
aromatase inhibitors in breast cancer treatment. 
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As per WHO database of developing and developed 
countries, breast cancer is the second leading cause of 
cancer death in women. About two-thirds of breast 
cancers are termed hormone-dependent breast cancer, 
which contains estrogen receptors (ER) and requires 
estrogen for tumour growth
1
. Aromatase is 
cytochrome P450 enzyme, responsible for the in situ 
biosynthesis of estrogen by converting the androgens 
including androstenedione and testosterone to the 
estrogen products, estrone and estradiol, respectively
2
. 
This enzyme is involved in the last step of the 
biosynthesis of estrogen from androgen and it is  
a potential target for reducing the level of estrogen in 
women and hence, prevent the estrogen dependent 
breast cancer
3
 (Figure 1). Currently, there are two 
types of aromatase inhibitors which are available in 
market, namely type I (steroidal) and type II  
(non-steroidal). The type I agents are either 
competitive inhibitors which are structurally related  
to the substrate or suicide inhibitors derived from 
androstenedione like 4-OHA or Exemestane. The  
type II agents behave as competitive inhibitors, 
coordinating one of their heteroatoms (N, S, and O) to 
the iron in the heme of the cytochrome
4,5
. The list of 
marketed aromatase inhibitors as per their generation 
based on clinical development is listed in Table I
6
. 
Chemically, chalcones or (E)-1,3-diphenyl-2-
propene-1-one are α, β- unsaturated carbonyl 
compounds
7
. Being a precursor of all of the other 
flavonoid groups, chalcones are very important 
biosynthetic compounds. Chalcones are also key 
precursors in the synthesis of many biologically 
important heterocycles such as benzothiazepine, 
pyrazolines, 1,4-diketones, and flavones
8
. Chalcone 
scaffold remained an obsession among researchers  
—————— 
List of Abbreviations: ADME/T: Absorption, Distribution, 
Metabolism, Excretion and Toxicity; PDB: Protein Data Bank; 
HEM(FE): Heme coordinating group; OPLS: Optimized 
Potentials for Liquid Simulations; RMSD: Root Mean Square 
Deviation; LRoF: Lipinski’ rule of five 
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in the 21
st
 century due to its simple chemistry, flexible 
structure, ease of synthesis and exhibiting broad 
spectrum biological activities like antimicrobial
9-15
, 
antimalarial
16,17
, anti-HIV
18-20
, antileishmanial
21,22
, 
antitubercular
23,24
, antioxidant
25,26
, Antihyperglycemic
27
, 
immunosuppressive property
28
, anti-inflammatory
29
, 
estrogenic and anti-proliferative
30
, antihelmintic
31
, 
analgesic
32
, antiulcer
33
 including anticancer activity 
through multiple mechanisms thus comprise a class 
with important therapeutic potential. Several  
natural and (semi) synthetic chalcones have  
shown anti-cancer activity due to their inhibitory 
potential against various targets namely mTOR
34
, 
aromatase and 17-β-hydroxysteroid dehydrogenase35, 
5α-reductase36-38, ABCG2/P-gp/BCRP39, topoisomerase-II40, 
HDAC/Situin-1
41
, cathepsin-K
42
, proteasome
43
, 
VEGF, VEGFR-2 kinase
44
, B-Raf
45
, NF-κB46, 
JAK/STAT signaling pathways
47
, CDC25B
48
, and 
tubulin
49
, etc. Chalcones have poor interaction with 
DNA and low risk of mutagenicity, while other 
anticancer drugs reported genotoxicity due to their 
interaction with amino groups in nucleic acids. In this 
regard, chalcones may be devoid of these side effects 
due to their structural flexibility
50
. 
Literature review on anticancer potency of 
chalcone highlights structural manipulation of both 
aryl rings and replacement of aryl rings with 
heteroaryl scaffolds. Methoxy (-OCH3) and hydroxy 
(-OH) substitutions on both the aryl rings (A and B) 
of the chalcones, depending upon their positions in 
the aryl rings appear to influence anticancer and other 
activities. Similarly, heterocyclic rings replaced with 
ring B in chalcones, also influence the anticancer 
activity shown by this class of compounds. Moreover, 
chalcones have structural similarities with estrogen 
and it is a precursor for the synthesis of flavonoids. 
As per shown in Figure 2, A and C rings of flavone 
and A ring of chalcone, its unsaturated keto (-C=O) 
group mimics the action of C and D rings of steroidal 
substrate of Type –II steroidal aromatase inhibitors51-53. 
Based on the above extensive literature review and 
various structural activity relationship of chalcone 
derivatives, various benzaldehyde and acetophenone 
derivatives are proposed for docking and in silico 
ADME study. The list of various acetophenone and 
benzaldehyde are summarized in Figure 3. So, the aim 
of the present study is to investigate the binding 
affinity of various chalcone derivatives on aromatase 
enzyme by molecular docking studies and compounds 
exhibiting good binding affinity are further checked 
for the ADME/T (drug likeness) properties by using 
Maestro 10.4, Schrodinger program. The successful 
application of docking and ADMET properties will 
result into discovering of novel and potential 
anticancer agents based on chalcone scaffold, which 
reduce the blood estrogen level by inhibiting 
aromatase enzyme in the treatment of breast cancer. 
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Figure 1 — Reaction mechanism for estrogen biosynthesis by aromatase enzyme 
 
 
Table I — List of marketed aromatase precursors 
Generation 
 
Type-I Inhibitors 
(Steroidal) 
Type-II Inhibitors 
(Non-steroidal) 
First Testolactone Aminoglutethimide 
Second Formestane Fadrozole 
Rogletimide 
Third Exemestane Vorozole 
Anastrozole 
Letrozole 
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Materials and Methods 
 
Retrieval of the 3-D structure of target proteins 
The crystal structure of human placental aromatase 
enzyme with PDB id 3S7S was retrieved from  
the protein data bank. The X-ray structure of  
protein contains aromatase enzyme complexed with 
exemestane as a ligand, the 3rd generation steroidal 
aromatase inhibitor and Cytochrome P450 19A1 
protein with Protoporphyrin IX containing HEM (FE) 
as a nonstandard residues
54
. 
 
Protein Preparation 
The crystal structure of aromatase enzyme was 
imported and constructed by a multistep process 
through the protein preparation wizard of Maestro 
(version 10.4, Schrodinger, LLC, New York, NY). 
The integrity protein structure was checked and 
missing residues/loop segments near the binding  
site were added using the prime program of maestro. 
For obtaining optimized and minimized energy 
conformation of the protein, hydrogen atoms were 
added and water molecules within 5A° periphery of 
the co-crystallized ligand were removed. The 
protonation states of entire system was maintained to 
pH range of 7.0 ± 2.0 using Epik v3.4 and the 
geometry optimization was performed to a maximum 
RMSD of 0.3 A° with the OPLS 2005 force field
55-57
. 
 
Ligand Preparation 
Chemdraw was used to draw the structure of 
chalcones derivatives. Further their energy was 
minimized by MOPAC program of Chem3D ultra-
software of Chemoffice, and single low energy 3D 
conformer with acceptable bond lengths and angles 
for each 2D structure was generated. Ligand 
structures were submitted to the energy minimization 
using the OPLS force field until the energy difference 
between subsequent structures was 0.001 kJ/molA. 
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Figure 2 — Chalcone moiety mimics the action of steroidal 
substrate and flavones 
 
 
Figure 3 — Selection of various chalcone derivatives for docking studies 
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The final ligand databases were in the mol2 format 
(3D structures). All possible tautomers of ligands by 
maintaining their stereochemistry were explored using 
LigPrep software, and it produced multiple 
conformations using confgen. Moreover, ligand 
ionization states were also generated by using Epik 
3.4 software. 
 
Molecular Docking Study 
The Glide program was used to predict the binding 
affinity between the designed chalcones derivatives 
and the active site of aromatase enzyme. During 
docking study, the receptor grid generation file was 
used, and it was defined as an enclosing box at the 
centroid of the co-crystallized ligand (i.e., 3S7S) to 
include the cofactor and substrate binding sites. The 
protein structure having a grid box of 30×30×30  
Å with a default inner box (10×10×10 Å) which was 
centred on the corresponding ligand. The LigPrep 
treated ligands were carried out to predict the binding 
pocket of protein 3S7S using the docking program. 
Initially, a soften potential docking with the van der 
waals radii scaling of 0.7 for the proteins was 
performed to retain the maximum number of 32 poses 
per ligand and residues within 5.0 Å of ligand poses 
were kept free to move in the Prime refinement step. 
Successively, single low energy 3D structure of 
ligands with correct chirality were docked with the 
binding site using the “extra precision (XP)” which 
uses MCSA (Monte Carlo Based Simulated 
Algorithm) based minimization. The best docked pose 
(with lowest G-score value) were obtained from Glide 
and analysed
55-58
. 
 
ADME Property Prediction and Analysis 
The QikProp program was used to access the drug-
like properties of all designed analogues. The software 
provided the ranges for comparing particular molecule 
properties with those of 95% of known drugs. The 
Lipinski’s rule of five (LRoF) and Veber’s rule were 
used to evaluate the acceptability of analogues and 
ensured the drug likeness properties, while performing 
rational drug design approach. Varied physicochemical 
descriptors as well as pharmaceutically important 
properties of chalcones derivatives were analysed. The 
prominent descriptors, which predict drug likeness 
properties of designed analogues, were reported. The 
H-bond Donor and acceptor, predicted water/gas 
partition and octanol/water coefficients, predicted 
aqueous solubility descriptors were considered to 
analyze the result
59,60
. 
Result and Discussions 
The docking score with binding energy and their 
corresponding intermolecular energy, electrostatic 
energy, hydrogen bonding and hydrophobic interaction 
for each class of flavonoids with aromatase enzyme 
(PDB ID: 3S7S) are given in Table II-V. Figure 4 
shows the interaction of Exemestane (steroidal 
aromatase inhibitor) with aromatase enzyme. The 
in silico predicted active sites for target protein  
(PDB ID: 3S7S) were MET374, ARG115, LEU372, 
LEU477, PHE134, VAL370,THR310, PHE221, 
VAL369, ASH309, SER478, ALA309, ALA306, 
TRP224, ILE305, HEM600, VAL373 The keto (-C=O) 
exemestane was interacted with MET 374 by  
H- bonding interaction. 
 
Docking analysis of 2-hydroxyphenyl- prop-2-en-1-
one (1A-1X) 
The 2-hydroxyphenyl- prop-2-en-1-one (1A-1X) 
derivative’s binding energy were in the range ~ -9.166 
to -5.069 kcal/mol (Table II). Amongst them, 
chalcone (1K, 1U, 1B) derivatives possessed lowest 
binding energy than selected ligand (Exemestane). 
Figure 5(A) has shown the binding interactions of  
1B with aromatase enzyme like H- bonding with  
LEU 372 and π- π stacking with ARG 115 and  
HEM 600. In 1K derivative, where ring’s “N” atom 
exhibits the H-bonding interaction with MET 374 and 
-OH (hydroxyl group) with ASH 309, where π- π 
stacking with ARG 115 [Figure 5(B)]. While 1U 
 
 
Figure 4 — Interaction of Exemestane with aromatase enzyme 
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derivatives -OH (hydroxyl group) interact with MET 
374/ LEU 372 and π- π stacking with ARG 115  
and TRP 224 [Figure 5(C)]. Other derivatives like 1S, 
1T, 1M, 1Q, 1F, 1N, 1J, 1R, 1G, 1I and 1H also 
possessed significantly good binding energy 
compared to ligand. 
Docking analysis of 2-hydroxy-4-Methoxyphenyl- 
prop-2-en-1-one (3A-3X) derivatives 
The 2-hydroxy-4-Methoxyphenyl- prop-2-en-1-one 
(3A-3X) derivative’s binding energy were in the 
range ~ –8.893 to -4.463 kcal/mol (Table III). 
Amongst them chalcone 3K and 3N derivatives  
 
 
 
Table II — Docking result of 2-hydroxyphenyl- prop-2-en-1-one (1A-1X) derivatives 
Sr. No Compd Docking score Glide energy Glide emodel XP HBond XP PhobEn XP Electro 
1 1K −9.166 −39.084 −57.379 −0.869 −0.918 −0.375 
2 1U −8.944 −39.422 −56.312 −1.564 −0.875 −0.561 
3 1B −8.285 −39.549 −54.571 −1.158 −0.826 −0.317 
4 1S −7.799 −38.848 −48.897 −0.96 −0.71 −0.375 
5 1T −7.664 −40.169 −53.543 −0.673 −0.671 −0.4 
6 1M −7.501 −34.006 2.971 −0.447 −0.35 −0.259 
7 1Q −7.428 −11.434 −23.659 −0.748 −1.574 −0.27 
8 1F −7.374 −32.866 −49.068 −0.96 −0.631 −0.356 
9 1N −7.37 −39.891 −50.234 0 −0.575 −0.184 
10 1J −7.297 −37.949 −54.489 −0.96 −0.705 −0.404 
11 1R −7.29 −37.781 −52.63 −0.96 −0.413 −0.359 
12 1G −7.207 −37.506 −49.288 −0.96 −0.698 −0.319 
13 1I −7.027 −37.336 −52.955 −0.96 −0.8 −0.377 
14 1H −6.921 −33.236 −49.682 −0.96 −0.8 −0.301 
15 1O −6.846 −25.365 9.938 −1.18 −0.125 −0.243 
16 1W −6.837 −37.047 −53.207 −1.553 −0.574 −0.26 
17 1P −6.803 −35.777 −44.156 −0.48 −0.553 −0.031 
18 1V −6.733 −38.003 −56.548 −0.96 −0.641 −0.427 
19 1X −6.489 −35.413 −54.344 −0.96 −0.927 −0.394 
20 1E −6.464 −30.791 −49.365 −0.96 0 −0.21 
21 1A −6.452 −26.032 −31.471 −0.48 −0.427 −0.026 
22 1C −6.35 −36.842 −29.267 −1.045 0 −0.294 
23 1D −6.275 −29.079 −40.706 −0.48 −1.072 −0.181 
24 1L −5.069 −26.98 −28.646 0 0 0.063 
25 EXE −8.354 −45.954 −41.842 −0.7 −0.657 −0.204 
 
 
 
Figure 5 — (A) Interaction of 2-hydroxyphenyl- prop-2-en-1-one derivative (1B) with aromatase enzyme; (B) Interaction of  
2-hydroxyphenyl- prop-2-en-1-one derivative (1K) with aromatase enzyme; (C) Interaction of 2-hydroxyphenyl- prop-2-en-1-one 
derivative 1U) with aromatase enzyme 
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possessed lowest binding energy than selected ligand 
(Exemestane). Figure 6(A,B) shows the binding 
interaction of 3K/3N with various amino acids of 
aromatase enzyme. In 3K derivative, where ring’s 
“N” atom exhibits the H-bonding interaction with 
MET 374 where π- π stacking was observed with 
ARG 115. While in 3N derivatives, -OH (hydroxyl 
group) interacted with ASH 309 and π- π stacking was 
 
 
Table III — Docking result of 2-hydroxy-4-Methoxyphenyl- prop-2-en-1-one (3A-3X) derivatives 
Sr. No Compd Docking score Glide energy Glide emodel XP HBond XP PhobEn XP Electro 
1 3K −8.893 −43.473 −63.109 −1.061 0 −0.279 
2 3N −8.535 −41.57 −24.641 −0.48 −0.798 −0.093 
3 3W −8.066 −40.558 −60.153 −1.163 0 −0.24 
4 3P −8.057 −26.293 67.948 −1.435 −0.751 −0.491 
5 3G −7.995 −36.659 −38.81 −1.484 −0.713 −0.378 
6 3M −7.885 −39.255 −48.938 −1.18 −0.125 −0.456 
7 3J −7.867 −38.228 −42.992 −1.459 −0.718 −0.414 
8 3T −7.802 −38.58 −38.385 −0.858 −0.791 −0.418 
9 3U −7.795 −38.083 −47.586 −0.696 −0.95 −0.251 
10 3I −7.291 −34.667 −43.591 −1.159 −0.663 −0.316 
11 3H −7.204 −37.457 −50.856 −0.887 −0.657 −0.395 
12 3X −7.203 −36.701 −49.346 −1.362 −0.777 −0.37 
13 3V −7.061 −37.447 −54.622 −0.975 −0.775 −0.436 
14 3A −6.855 −25.407 6.665 −0.96 −0.125 −0.278 
15 3S −6.751 −32.533 −33.415 −0.96 0 −0.032 
16 3F −6.264 −25.899 −34.494 −0.96 −0.05 0.008 
17 3C −6.201 −17.81 26.203 −0.96 −0.251 −0.113 
18 3L −6.023 −30.021 −25.431 −0.48 0 0.11 
19 3E −5.99 −32.326 −36.87 −0.48 −0.05 0.096 
20 3R −5.932 −31.133 −51.06 −0.645 −0.025 −0.006 
21 3O −5.805 −25.289 −13.223 −0.99 0 −0.133 
22 3B −5.364 −41.451 −58.927 −0.7 0 −0.351 
23 3Q −4.652 −13.003 11.789 −0.48 0 0.045 
24 3D −4.463 −18.129 −6.353 −0.943 0 −0.157 
25 EXE −8.354 −45.954 −41.842 −0.7 −0.657 −0.204 
 
 
 
Figure 6 — (A) Interaction of 2-hydroxy-4-Methoxyphenyl- prop-2-en-1-one derivative (3K) with aromatase enzyme; (B) Interaction of 
2-hydroxy-4-Methoxyphenyl- prop-2-en-1-one derivative (3N) with aromatase enzyme 
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observed with ARG 115. Other derivatives like 3W, 
3P, 3G, 3M, 3T, 3U, 3I, 3H, 3X also possessed 
significantly good binding energy compared to ligand. 
 
Docking analysis of 1- hydroxynaphthalen-2-yl-
prop-2-en-1-one (5A-5X) derivatives 
The 1- hydroxynaphthalen-2-yl-prop-2-en-1-one 
(5A-5X) derivative’s binding energy were in the range 
~ -9.915 to -4.228 kcal/mol.(Table IV) Amongst them, 
chalcone 5K and 5U derivatives possessed lowest 
binding energy than selected ligand (Exemestane). 
Figure 7(A,B) was shown the binding interactions of 
5K/5U with various amino acids of aromatase enzyme. 
In 5K derivative, where ring’s “N” atom exhibits the 
H-bonding interaction with MET 374 where π- π 
stacking observed with ARG 115 and TRP224. While 
 
Table IV — Docking result of 1- hydroxynaphthalen-2-yl-prop-2-en-1-one (5A-5X) derivatives 
Sr. No Compd Docking score Glide energy Glide emodel XP HBond XP PhobEn XP Electro 
1 5K −9.195 −34.986 −33.108 −0.7 0 −0.476 
2 5U −8.867 −31.148 −14.617 −1.855 −0.802 −0.408 
3 5T −8.224 −23.603 8.202 −0.7 −0.833 −0.456 
4 5W −7.915 −29.375 −47.162 −0.7 −0.135 −0.213 
5 5S −7.615 −31.033 −25.228 −0.48 −0.793 −0.136 
6 5A −7.421 −29.736 −6.404 −0.987 −0.61 −0.227 
7 5E −7.305 −24.971 −16.924 −0.48 −0.914 −0.189 
8 5D −7.07 −22.831 4.393 −0.48 −0.817 −0.223 
9 5X −6.985 −34.279 −41.778 −0.48 0 −0.055 
10 5P −6.911 −15.901 10.788 −0.48 0 −0.072 
11 5J −6.884 −27.727 −18.321 −0.48 −0.717 −0.143 
12 5F −6.783 −23.192 −9.686 −0.48 −0.913 −0.173 
13 5V −6.679 −31.907 −39.85 −0.48 0 −0.033 
14 5I −6.671 −27.071 −18.945 −0.48 −0.688 −0.05 
15 5H −6.669 −27.25 −24.207 −0.48 −0.774 −0.104 
16 5Q −6.361 −9.706 17.211 −0.48 −1.001 −0.153 
17 5B −6.359 −33.857 −27.482 −1.18 0 −0.45 
18 5L −6.168 −30.459 −27.682 −0.48 −0.556 −0.091 
19 5M −5.727 −13.027 16.102 −0.48 0 −0.121 
20 5R −5.656 −30.696 −15.427 −0.48 0 −0.101 
21 5N −5.591 −26.783 1.094 −0.72 0 −0.08 
22 5G −5.402 −26.038 5.544 −0.48 0 −0.183 
23 5C −4.228 −16.019 11.755 0 0 −0.046 
24 5K −9.195 −34.986 −33.108 −0.7 0 −0.476 
25 EXE −8.354 −45.954 −41.842 −0.7 −0.657 −0.204 
 
 
Figure 7 — (A) Interaction of 1- hydroxynaphthalen-2-yl-prop-2-en-1-one derivative (5K) with aromatase enzyme; (B) Interaction of 1- 
hydroxynaphthalen-2-yl-prop-2-en-1-one derivative (5U) with aromatase enzyme 
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in 5U derivatives -OH (hydroxyl group) interacted with 
GLN 218/ASH 309 and π- π stacking was observed 
with HIE 480, PHE 221 and TRP224. Other derivatives 
like 5T, 5W, 5S, 5A, 5E and 5D also possessed 
significantly good binding energy compared to ligand. 
 
Docking analysis of 2, 4-dihydroxyphenyl- prop-2-
en-1-one (9A-9X) derivatives 
The 2, 4-dihydroxyphenyl- prop-2-en-1-one (9A-9X) 
derivative’s binding energy were in the range ~ -8.649 
to -4.485 kcal/mol.(Table V) Amongst them chalcone 
9S, 9K, 9N and 9F derivatives possessed lowest 
binding energy than selected ligand (Exemestane). 
Figure 8 has shown the binding interactions of 9S, 
9K, 9N and 9F with various amino acids of aromatase 
enzyme. The 9K derivative’s hydroxyl (-OH) group 
exhibits the H-bonding interaction with ALA 306 and 
pyridine ring’s “N” atom exhibit H- bonding 
interaction with MET374 where π- π stacking 
observed with PHE 134 and  
 
 
 
 
Figure 8 — (A) Interaction of 2, 4-dihydroxyphenyl- prop-2-en-1-one derivative (9F) with aromatase enzyme; (B) Interaction of 2,  
4-dihydroxyphenyl- prop-2-en-1-one derivative (9K) with aromatase enzyme; (C) Interaction of 2, 4-dihydroxyphenyl- prop-2-en-1-one 
derivative (9N) with aromatase enzyme; (D) Interaction of 2, 4-dihydroxyphenyl- prop-2-en-1-one derivative (9S) with aromatase 
enzyme 
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Table V — Docking result of 2, 4-dihydroxyphenyl- prop-2-en-1-one (9A-9X) derivatives 
Sr. No Compd Docking score Glide energy Glide emodel XP HBond XP PhobEn XP Electro 
1 9S −8.649 −41.966 −49.757 −1.625 −0.766 −0.542 
2 9K −8.601 −38.436 −58.602 −1.616 −0.579 −0.296 
3 9N −8.506 −39.916 −55.841 −1.625 −0.663 −0.582 
4 9F −8.444 −39.905 −49.629 −1.568 −0.694 −0.531 
5 9R −8.303 −41.397 −59.654 −1.625 −0.583 −0.557 
6 9I −7.905 −42.777 −56.426 −1.625 −0.479 −0.593 
7 9U −7.834 −43.362 −61.629 −1.74 −0.596 −0.599 
8 9G −7.728 −39.929 −50.354 −1.625 −0.3 −0.512 
9 9E −7.5 −29.25 −46.62 −1.357 −0.696 −0.252 
10 9X −7.436 −43.429 −66.143 −1.625 −0.371 −0.597 
11 9B −7.432 −38.844 −57.954 −1.625 −0.284 −0.491 
12 9T −7.424 −37.56 −51.439 −0.7 −0.784 −0.334 
13 9V −7.419 −42.882 −64.921 −1.625 −0.618 −0.59 
14 9H −7.372 −39.489 −58.58 −1.625 −0.428 −0.474 
15 9M −7.116 −39.255 −48.938 −1.18 −0.125 −0.456 
16 9W −7.009 −42.409 −64.099 −1.625 −0.569 −0.565 
17 9P −6.966 −33.299 −35.295 −1.18 −0.45 −0.232 
18 9D −6.288 −29.733 −28.403 −0.424 −1.165 −0.115 
19 9C −6.163 −32.747 −33.097 −1.18 0 −0.49 
20 9L −6.049 −25.321 −28.771 −1.18 −0.275 −0.264 
21 9Q −5.943 −23.781 −21.677 −0.192 −1.211 −0.089 
22 9A −5.486 −33.328 −33.739 −0.7 0 −0.225 
23 9O −4.594 −26.048 3.568 −0.028 −0.05 −0.058 
24 9J −4.485 −32.177 −47.226 −0.813 −0.025 0.086 
25 EXE −8.354 −45.954 −41.842 −0.7 −0.657 −0.204 
 
Table VI — In silico predicted ADME/T properties of Chalcone Derivatives by using QikProp 
Compd H-Bond Donor H-Bond Acceptor QPlogPoct QPlogPw QPlogPo/w QPlogS 
(8.0-43.0)* (5.0-48.0)* (−2.0-6.0)* (−6.0-0.5)* 
1K 0 3.25 10.854 6.052 2.48 −2.671 
1U 2 3.25 14.137 8.763 2.034 −2.919 
1B 1 2.5 12.123 6.687 2.69 −3.314 
3K 0 4 11.665 6.287 2.449 −2.789 
3N 0 4 12.627 5.454 3.566 −3.896 
5K 0 3.25 12.704 6.539 3.383 −3.654 
5U 2 3.25 16.329 9.52 3.117 −4.343 
9S 1 2.5 12.907 6.372 3.218 −4.072 
9K 1 4 13.037 8.218 1.879 −2.89 
9N 1 4 13.867 7.299 2.885 −3.515 
9F 1 2.5 12.787 6.4 3.179 −4.067 
Exemestane 0 4 13.942 6.081 3.036 −3.747 
* Standard value of properties 
 
ARG 115 [Figure 8(B)]. In 9S/9N/9F derivatives two 
-OH (hydroxyl group) interacted with MET374/LEU 
372 and π- π stacking was observed with HEM 600 
(heme coordinating moiety) [Figure 8(A,C,D)]. Other 
derivatives like 9R, 9I, 9U, 9G, 9E, 9X, 9B, 9T, 9V, 
9H, 9M and 9W also possessed significantly good 
binding energy compared to ligand. 
In silico ADMET Study 
All designed compounds were checked for their 
ADME/T properties by QikProp (V4.6, 2015). Among 
them, ADMET properties of eleven (1K, 1U, 1B, 3K, 
3N, 5K, 5U, 9S, 9K, 9N, and 9F) compounds which 
having good docking score and binding affinity 
compared with standard ligand (Exemestane) are 
INDIAN J. CHEM., SEC B, FEBRUARY 2020 
 
 
292 
reported in Table VI, these analogues have also 
shown good drug likeness properties. 
 
Conclusion 
The amino acid of enzyme and ligand interaction is 
important while drug designing and discovery study. In 
the present work; binding, interactions and drug 
likeness properties of chalcone derivatives with 
aromatase enzyme have been studied using 
Schrodinger software. During the study, it was 
observed that majority of the compounds have shown 
significant binding interactions with enzyme. The 
hydrogen bond interactions and π- π stacking also 
contributed to the strong binding of these compounds 
to the binding site of aromatase. It was observed that 
3
rd
 and 4
th
 position “B” ring of chalcone derivatives 
substituted with –OH (hydroxyl), -OMe (methoxy) and 
Cl/Br (halogens) are important to evoke aromatase 
inhibition. The “N” atom of 4-pyridine derivatives (1K, 
3K, 5K and 9K) were found to be interacted with MET 
374 by strong H- Bonding. So, H- bonding interactions 
were predominant in all the classes of compounds 
taken for study and were found to be important for 
inhibition. Based on Quik Pro analysis of the all the 
analogues, it was proved that, those compounds having 
better drug like properties and following the Lipinski 
rule of five (LRoF). 
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